Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC)

Author(s): Cornelia Liedtke*, Achim Rody

Journal Name: Reviews on Recent Clinical Trials

Volume 12 , Issue 2 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Background: Patients with triple negative breast cancer (TNBC) are characterized by an unfavorable prognosis particularly when not responding well to anthracycline-taxane chemotherapy. This is due to a more aggressive biology in some cases but most importantly to a lack of agents other than conventional chemotherapy. Hence, there is an urgent need to optimize therapy of patients with TNBC in order to improve prognosis.

Objective: The objective of this review is to present the current understanding of TNBC biology and give an insight of current therapeutic concepts in the neoadjuvant treatment setting.

Method: Current literature has been selected based on a literature search and current therapeutic concepts are explained and commented on.

Results: Novel therapeutic concepts for patients with TNBC focus on a) chemotherapy optimization through alternate scheduling, dosing or alternative/additional chemotherapeutic agents, b) evaluation of novel targeted agents and c) identification of clinically relevant patient subgroups through prognostic/ predictive biomarkers to enable a more personalized treatment approach. Potential novel therapeutic targets include inhibition of Poly-A-Ribose-Polymerase (PARP), checkpoint inhibition and antiandrogenic agents.

Conclusion: Treatment of TNBC is currently been optimized both through optimization of chemotherapy and introduction of novel targeted agents which should enhance treatment response rates in the future.

Keywords: BRCA1/2, checkpoint inhibition, chemotherapy PARP inhibition, platinum-salts, triple negative breast cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [73 - 80]
Pages: 8
DOI: 10.2174/1574887112666170307095945
Price: $65

Article Metrics

PDF: 50
PRC: 1